Sustained release intraocular implants and related methods

• US 8,298,570 B2
• Filed: 02/14/2008
• Issued: 10/30/2012
• Est. Priority Date: 04/30/2004
• Status: Active Grant

• Current Assignee: Allergan Incorporated (Abbvie Incorporated)
• Original Assignee: Allergan Incorporated (Abbvie Incorporated)
• Inventors: Huang, Glenn T, Nivaggioli, Thierry
• Primary Examiner(s): AZPURU, CARLOS A
• Application Number:
  US12/031,659
• Publication Number:
  US 20080138382A1
• Time in Patent Office: 1,720 Days
• Field of Search: None
• US Class Current: 424/428
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/573 substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• CPC Class Codes: A61K 31/58 containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin digitoxin A61K31/7048
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61K 9/0092 Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/14 Decongestants or antiallergics

Abstract

Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants may be placed in an eye to treat one or more ocular conditions. The steroid is released from the implant for more than about two months, and may be release for more than several years.

Claims

1. A method of treating an ocular condition of a patient, comprising the step of placing a biodegradable intraocular implant in an ocular site or region of an eye of the patient to provide a therapeutically effective amount of a steroid to the patient, wherein said implant comprises a steroid associated with a biodegradable polymer matrix, wherein the biodegradable polymer matrix comprises a mixture of first and second biodegradable polymers, wherein the first biodegradable polymer is a poly(D,L-lactide-co-glycolide) having terminal acid groups and an inherent viscosity of about 0.16 dl/g to about 0.24 dl/g, and the second biodegradable polymer is a poly(D,L-lactide) having terminal acid groups and an inherent viscosity of about 0.16 dl/g to about 0.24 dl/g, and wherein the implant releases drug at a rate effective to sustain release of a therapeutically effective amount of the steroid from the implant.

2. The method of claim 1, wherein the ocular condition is an inflammation of the eye.

3. The method of claim 1, wherein the implant is placed in the posterior of the eye.

4. The method of claim 1, wherein the implant is placed in the eye with a trocar.

5. The method of claim 1, wherein the implant is placed in the eye with a syringe.

6. The method of claim 1, further comprising a step of administering a therapeutic agent in addition to the steroid to the patient.

7. The method of claim 1, wherein the biodegradable polymer matrix comprises a 1:

1 mixture of the first and second biodegradable polymers.

8. The method of claim 1, wherein the ocular condition is uveitis.

9. The method of claim 1, wherein the steroid is a fluocinolone, a triamcinolone, or a mixture of fluocinolone and triamcinolone.

10. The method of claim 1, wherein the steroid is a fluocinolone, a triamcinolone, or a mixture of fluocinolone and triamcinolone.